However, even in prostate cancer, AR can have opposing effects on cell cycle regulation, depending on ligand concentration, duration of treatment and the extent of GOF alterations in AR signaling in the context of malignant transformation (Chatterjee et al., 2019; Gao et al., 2016; Litvinov et al., 2006). The gene discussed is AR; the disease is prostate cancer.